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A b s t r a c t
Introduction: Barrett’s oesophagus (BE) is a result of replacement of the mucosa of the distal oesophagus by meta-
plastic columnar epithelium. The role of cyclooxygenase-2 (COX-2) and chronic inflammation in the progression of BE
toward adenocarcinoma of the oesophagus is emphasized. Argon plasma coagulation (APC) allows for effective abla-
tion of metaplastic mucosa. It is believed that effective suppression of gastric secretion with proton pump inhibitors
(PPI) promotes squamous cell re-epithelialization and a decrease in expression of some biomarkers including COX-2.
A similar effect can be achieved by the anti-reflux procedure.
Aim: To evaluate the usefulness of COX-2 expression in determining the risk of malignant transformation in patients
with BE.
Material and methods: Patients from two out of three study groups underwent APC ablation of metaplastic mucosa
combined with chronic PPI administration (group A) or laparoscopic Nissen fundoplication (group B). Controls (group K)
were submitted only to PPI treatment. Expression of COX-2 was evaluated in fresh-frozen biopsy specimens obtained
from the distal oesophagus in all 60 patients before and 12 months after treatment.
Results: Overexpression of COX-2 was found in 41 patients (68.3%). The highest degree of COX-2 expression was doc-
umented in patients with dysplasia. After treatment overexpression of COX-2 was markedly reduced in patients from
groups A and B, which correlated well with histopathological findings. Controls did not show important changes in
COX-2 expression.
Conclusions: Significant correlation of the degree of COX-2 overexpression with histopathological findings points to
the possible use of this biomarker as a valuable indicator of the risk of malignant transformation in patients with BE.
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Introduction
Barrett’s oesophagus (BE) is a result of replace-
ment of the mucosa of the distal oesophagus by
metaplastic columnar epithelium. According to for-
mer definitions it must involve at least 3 cm to fulfil
the diagnostic criteria – so-called “classical” or “long
segment” BE. Currently if the lesions are found in
a segment shorter than 3 cm it is classified as “short
segment” [1]. Cases of metaplasia presenting only as
irregularities or patches of properly localized Z-line
are referred to as “ultrashort” BE by some authors. 
Barrett’s oesophagus is believed to be an end
stage of gastroesophageal reflux disease (GERD) as it
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is significantly more frequent among patients with
reflux than in the general population. Even though it
is generally recognized as a condition preceding
development of adenocarcinoma of the gastroe-
sophageal junction, the exact mechanisms of onco-
genesis are not clear. Identification of those correla-
tions seems crucial for selection of the group of
patients at particular risk. Some increase (according
to various authors ranging from 60% to 90%) in the
incidence of adenocarcinoma of the distal oesopha-
gus associated with BE has been observed [2, 3]. This
could be attributed to higher incidence of GERD. 
Progression of Barrett’s metaplasia into oeso -
phageal adenocarcinoma (EAC) is a result of chronic
irritation of the mucosa by refluxate [4, 5]. Even
though BE is reversible the chronic inflammation may
promote progression of BE into EAC [6]. Pathogenesis
of BE is related to the character of the refluxate.
A correlation between bile salt concentration and 
the degree of mucosal damage has been demon-
strated [7].
It is nowadays clear that identification of the pres-
ence of metaplasia (gastric and/or intestinal) and the
degree of dysplasia in the distal oesophagus is not
sufficient for proper evaluation of the stage of the
disease. The use of more precise markers of the risk
of EAC is suggested. The value of more than 60 bio-
markers is currently undergoing detailed studies;
among them, cyclooxygenase-2 (COX-2) is believed
to be one of the most promising [8, 9]. It has been
demonstrated that chronic irritation caused by expo-
sure to bile salts results in enhanced expression of
COX-2 in the metaplastic mucosa [10]. Numerous
studies point to increased activity of COX-2 and
prostaglandin E2 (PGE2) as factors promoting chronic
inflammation and progression of carcinogenesis [7].
Prostaglandins – the main metabolites of the arachi-
donic acid cascade – seem to be potent factors in car-
cinogenesis modulating cellular adherence, the
immune response, mitogenesis, cell proliferation,
apoptosis and angiogenesis [7]. Overexpression of
COX-2 through mechanisms involving protein Bcl-2
causes inhibition of apoptosis and concomitant
enhancement of angiogenesis, which promotes pro-
gression of cancer [11, 13]. This is further supported
by the observation of excessive expression of COX-2
in human neoplasms of the GI tract, breast, lung,
uterus and prostate [10]. The same overexpression
was also found in patients with BE, especially in cas-
es of high-grade dysplasia and adenocarcinoma 
[10, 16, 17]. It might be thus assumed that expression
of COX-2 may be a useful marker of early stages of
carcinogenesis [18].
Barrett’s oesophagus is undoubtedly a serious
complication of GERD, and thus might be considered
a consequence of malfunction of the lower oeso -
phageal sphincter (LES). The management of BE 
is based on the treatment of oesophageal reflux of
gastroduodenal content. Treatment of Barrett's
patients includes both methods applied typically in
therapy of uncomplicated GERD and specific tech-
niques [19, 20]. This can be achieved by chronic use
of medications decreasing gastric acid secretion –
mainly proton pump inhibitors (PPI). Similarly, anti-
reflux surgery by restoration of the high pressure
zone in the gastroesophageal junction decreases
exposure of the distal oesophagus to irritating gas-
troduodenal refluxate [21]. Both methods are used in
combination with various techniques of endoscopic
mucosa ablation. All those procedures, including
argon plasma coagulation (APC), promote re-epithe-
lialization in the region of the GE junction [22]. 
There are no uniformly accepted standards of
management of BE so far. It might be however
assumed that effective treatment of GERD combined
with ablation of metaplastic mucosa should decrease
the risk of carcinogenesis. Accepting expression of
COX-2 as a valuable marker of this process, it may
prove useful in monitoring the treatment results. 
Aim 
The aim of the study was to evaluate the expres-
sion of COX-2 in the monitoring of treatment results
of patients with BE. Patients were enrolled in three
study groups: group A – treated by APC ablation of BE
combined with PPI; group B – APC ablation and anti-
reflux procedure (LNF); and group K – PPI used as
a sole method of management. 
Material and methods
Material
The study group consisted of 60 patients with BE
treated at the 2nd Department of Surgery UJ CM in
Krakow during 2005-2008. The inclusion criteria for
this study comprised: endoscopic picture of BE con-
firmed by histologically proven glandular metaplasia
in the distal oesophagus. There were 30 patients
treated by APC ablation of metaplastic mucosa fol-
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lowed by administration of 80 mg of pantoprazole
(group A). In group B, consisting of 20 patients, APC
ablation was combined with laparoscopic Nissen fun-
doplication (LNF). There were 10 controls (group K)
who refused endoscopic ablation and were treated
with pantoprazole (80 mg per day) only. 
There were 19 males (63.3%) and 11 females
(36.7%) in group A. Mean age was 54.9 years. Group B
consisted of 16 men (80%) and 4 women (20%).
Mean age was 47.3 years. There were 7 male (70%)
patients and 3 females (30%) in the control (K) group.
Mean age was 50.1 years. The differences in sex ratio
and age were statistically insignificant (NS). Detailed
demographic data of the study subjects are present-
ed in Table I.
Methods
All patients underwent gastroscopy with evalua-
tion of the entire upper GI tract to exclude other
pathology of the oesophagus, stomach or duodenum.
In all subjects with endoscopic suspicion of BE biop-
sy samples were obtained from the gastroesophageal
junction for histological evaluation and assessment
of the expression of COX-2. Throughout the entire
study during all endoscopies biopsies were taken
from all 4 quadrants of the gastroesophageal junc-
tion every one centimetre starting from the line of
gastric folds to the Z-line (Figure 1).
For evaluation of the expression of COX-2 RNA
was isolated with Trizol. After purification of RNA and
quality testing the RT-PCR reaction was performed.
cDNA synthesized in the process of reverse transcrip-
tion served as a matrix for PCR gene amplification
using specific primers. Electrophoresis on 1.5%
agarose gel with ethidium bromide was used for visu-
alization and analysis of PCR products. Densitometric
evaluation of electrophoretic bands was performed
with Kodak Digital Science software. 
Patients with confirmed BE who refused any inva-
sive management were enrolled in a control group (K)
and received pantoprazole 80 mg per day for 12
months (Figure 1).
The remaining 50 patients were subjected to
endoscopic ablation of the mucosa of the distal
oesophagus with APC. During each session of the
endoscopic procedure 1–2 quadrants of the mucosa
were destroyed. In the case of involvement of 3 or 
4 segments endoscopic ablation of consecutive quad-
Group N Sex Age [years] Value of p
Female Male Mean SD Min. Max.
A 30 11 19 54.9 10.9 26 72 NS
36.7% 63.3% – – – –
B 20 4 16 47.3 12.2 30 76 NS
20.0% 80.0% – – – –
K 10 3 7 50.1 10.8 33 65 NS
Table I. Demographics of the study groups
BE (+) gastroscopy 
(histopathology, COX-2, endoscopic tattoo)
APCGroup K
Group A Group B
PPI LNF
PPI





Control gastroscopy (histopathology + COX-2)
BE – Barrett’s oesophagus, PPI – proton pump inhibitor, LNF – laparoscopic
Nissen fundoplication, APC – argon plasma coagulation
Figure 1. Study design
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Group N Normal expression Degree of COX-2 overexpression Value 
(– or +/–)
+ ++ +++ Mean SD Min. Max.
of p
A 30 9 13 3 5 1.62 0.86 1 3 NS
61.9% 14.3% 23.8%
B 20 7 8 4 1 1.46 0.66 1 3 NS
61.5% 30.8% 7.7%
K 10 3 3 3 1 1.71 0.76 1 3 NS
42.9% 42.9% 14.2%
Table II. The degree of overexpression of COX-2 in study groups before treatment
rants was performed after 4–6 weeks. After comple-
tion of endoscopic therapy follow-up endoscopy with
biopsy was performed 6 weeks later. In the case of
histologically documented failure the procedure was
repeated until full eradication of metaplastic mucosa
was achieved. Patients with a confirmed positive
response to endoscopic treatment were assigned to
two groups – A and B. 
Patients from group A refused anti-reflux surgery
and were treated with pantoprazole 80 mg per day
for 12 months. Group B consisted of patients in
whom endoscopic ablation was combined with
laparoscopic Nissen fundoplication. Patients from all
groups (A, B and K) were submitted to follow-up
endoscopy after 12 months.
Results
Before treatment, most patients presented with
overexpression of COX-2 in biopsies from the gas-
troesophageal junction. Distribution of high, moder-
ate and low overexpression of COX-2 was compara-
ble in all study groups (Table II).
In group A – subjects treated with a combination
of APC and PPI – increased expression of COX-2 was
found in 21 out of 30 patients. High overexpression of
COX-2 (+++) was present in 5 patients (23.8%) with
low-grade and moderate dysplasia. In 3 expression
(14.3%) was only moderately enhanced, while in 
13 overexpression (61.9%) was regarded as low (+). In
the remaining 9 patients expression of COX-2 in biop-
sy specimens of metaplastic mucosa of the distal
oesophagus was normal (Table II). 
In group B – subjects treated with a combination
of APC and LNF – overexpression of COX-2 was found
in 13 out of 20 patients. In most of them overexpres-
sion was low (+) – 8 patients (61.5%), or moderate
(++) – 4 patients (30.8%). High overexpression of
COX-2 (+++) was found in 1 patient (7.7%) with low-
grade and moderate dysplasia (Table II). 
In controls from group K – treated with PPI only –
overexpression of COX-2 was found in 7 out of 
10 patients. The highest level of overexpression (+++)
was found in 1 patient (14.2%) with low-grade or
moderate dysplasia. In 3 patients (42.9%) overex-
pression was regarded as moderate (++) and in the
other 3 (42.9%) as low (+). In 3 patients from the con-
trol group expression of COX-2 was normal (Table II). 
In the initial evaluation of biopsy specimens the
degree of COX-2 overexpression was related to the
histological type of glandular metaplasia in all study
groups. In 1 patient with gastric metaplasia (GM) the
level of COX-2 overexpression was low (+). In the
largest group of 42 patients with complete intestinal
metaplasia (IM [+]) without dysplasia low (+) overex-
pression of COX-2 was most frequent (47.6%). In
40.5% of patients from this group expression of COX-2
was normal. Only 12% of patients had moderate
overexpression (++). Among 6 patients with incom-
plete intestinal metaplasia (IM [–]) without dysplasia
2 (33.3%) had normal expression of COX-2, another 
2 (33.3%) had low (+) and the remaining 2 (33.3%)
a moderate (++) level of overexpression of COX-2. 
In patients with IM (+) and low-grade or moderate
dysplasia overexpression of COX-2 was high (+++) in
75% of patients and moderate (++) in 25% of
patients. Among 3 patients with IM (–) with low or
moderate dysplasia each had a different level of 
COX-2 overexpression (Figure 2).
Second gastroscopy with biopsy of the gastroe-
sophageal junction for histology and assessment of
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the degree of COX-2 expression was performed after
12 months. Analysing only the presence or absence of
overexpression (omitting its severity), its incidence
was statistically significantly lower in patients treated
with APC ablation of metaplastic mucosa (group A
and B) as compared to initial values. Overexpression
of COX-2 was found in 6 patients from group A
(combination of APC and PPI) and 3 from group B
(combination of APC and LNF). The difference
between group A and B was not significant (Table III).
The expression of COX-2 in the control group (K) did
not change after 12 months of PPI treatment. The dif-
ference between both groups treated with APC 
(A and B) and controls (K) was statistically significant
(Table III). 
The degree of COX-2 expression after treatment
was the subject of further analysis. Among patients
from group A (APC + PPI) low overexpression (+) was
found in 4 (13.3%) and moderate in 2 (6.7%). Those
last 2 patients initially had IM (+) without dysplasia. In
the follow-up evaluation, after 12 months of treat-
ment none of the patients had high overexpression
(+++) of COX-2. In 24 patients (80%) from this group
expression of COX-2 was normal (Table IV). 
Only 3 patients (15%) from group B (APC + LNF)
showed increased expression of COX-2 in the follow-
up evaluation performed after 12 months. In 2 of
them (10%) the degree of overexpression was
assessed as low (+) and in 1 (5%) as moderate (++).
This last patient initially had IM (–) with low-grade
dysplasia in the first evaluation. None of the patients
had high overexpression of COX-2 (+++) in the follow-
up examination (Table IV). 
Among controls (group K) treated for 12 months
only with PPI excessive expression of COX-2 was
found in 7 patients (70%). As in the initial evaluation,
high COX-2 overexpression (+++) was demonstrated
in 1 patient. In the follow-up examination overexpres-
sion of COX-2 was low (+) in 4 patients and moderate
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Group N Normal expression (– or +/–) Degree of COX-2 overexpression
+ ++ +++
A 30 24 (80%) 4 (13.3%) 2 (6.7%) 0
B 20 17 (85%) 2 (10%) 1 (5%) 0
K 10 3 (30%) 4 (40%) 2 (20%) 1 (10%)
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GM IM (+) IM (–) IMD (+) D IM (–) D






Group N When        Expression of COX-2 Value of p
Absent Present
A 30 Before 9 21 < 0.001
After 24 6
B 20 Before 7 13 < 0.001
After 17 3
K 10 Before 3 7 NS
After 3 7
Table III. Changes of COX-2 expression after
treatment compared to baseline
A : B – NS; A : K – p < 0.001; B : K – p < 0.001
GM – gastrin metaplasia, IM (+) – complete intestinal metaplasia, 
IM (–) – incomplete intestinal metaplasia, IM (+) D – complete intestinal
metaplasia with low-grade or moderate dysplasia, IM (–) D – incomplete
intestinal metaplasia with low-grade or moderate dysplasia 
Figure 2. The degree of COX-2 overexpression
related to histological type of glandular meta-
plasia 
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(++) in 2 patients. In 3 patients at the beginning and
after completion of the study protocol expression of
COX-2 was normal (Table IV). 
Discussion 
Identification of the factors leading to the devel-
opment of BE and consequently adenocarcinoma has
been the subject of research for many years. Chronic
irritation of the mucosa of the distal oesophagus by
reflux is crucial. It remains however unclear why
some patients develop only reflux oesophagitis,
while others develop Barrett’s metaplasia. 
A uniform diagnostic and therapeutic algorithm
has not been reached yet. Various factors have been
blamed for this, including variability of the clinical
picture, frequent modifications of the definition of BE
and poorly understood pathogenesis of this disease
[23]. There is however general agreement that the
main goal of management is treatment of GERD [24].
The normalization of pH in the gastroesophageal
junction is crucial and is most frequently achieved by
administration of PPI. This treatment results in an
excellent symptomatic response and reduction of 
the inflammation of the mucosa of the distal oeso -
phagus. 
Undoubtedly studies on the molecular back-
ground for the sequence metaplasia-dysplasia-
carcinoma may be the key to understanding the
details of the pathogenesis of BE. Defects of apopto-
sis appear to be particularly important in the devel-
opment of dysplasia and adenocarcinoma in these
patients. One of the proposed mechanisms of dis-
torted pathways of programmed cell death is physio-
logically increased synthesis of the factors limiting
this process. Cyclooxygenase-2 inhibits apoptosis in
vitro [25]. In the process of carcinogenesis overex-
pression of COX-2 interferes with regulation of
metabolism of arachidonic acid. This leads to the
increased production of prostaglandins, which influ-
ences the proliferation of the cells, enhances angio-
genesis, reduces apoptosis, stimulates tumour
growth, modulates the immune response and
reduces the adhesion of the cells, leading in conse-
quence to progression of the neoplasm [7]. Irritation
of metaplastic mucosa by acidic gastric content acti-
vates mitogen-activated protein kinase (MAPK),
resulting in increased inflow of proliferative signals to
the cell nucleus [12]. Overexpression of this enzyme
has been found in numerous gastrointestinal cancers,
including oesophageal adenocarcinoma [9]. In the
available literature, some evidence for the presence
of increased expression of COX-2 in metaplastic
mucosa in patients with BE can be found. It is
believed that overexpression of this enzyme is in
close correlation with the persistence of chronic
inflammatory processes, which promotes carcino-
genesis [26]. In this study overexpression of COX-2
was documented in most patients (Table II). A corre-
lation between increased expression of COX-2 and
the degree of dysplasia was found in the presented
material (Figure 1). Similar conclusions can be found
in the publication of Schirvani [10]. In his study the
synergistic role of acid and bile contained in the
refluxate as factors responsible for increased expres-
sion of COX-2 was highlighted.
According to the opinion of some authors, effec-
tive suppression of gastric acid secretion can lead not
only to re-epithelialization of the squamous mucosa,
but also to reduction of the expression of several bio-
markers characteristic for the process of proliferation
[27]. In this study only in one patient from the control
group (K), in whom overexpression of COX-2 was not
present both before and after treatment, did meta-
plasia disappear completely after one year of PPI
administration. The highest expression in this group
was observed in a patient with moderate grade 
dysplasia associated with complete intestinal meta-
plasia. In this case however, the final expression 
of COX-2 did not change compared to baseline after
12-month therapy with pantoprazole 80 mg daily
(Table III). It seems therefore that the use of proton
pump inhibitors as a sole mode of treatment does
not significantly influence the degree of expression
of COX-2 in patients with Barrett’ oesophagus. How-
ever, the size of the study groups and the short time
of observation do not allow for definite conclusions,
and further studies are needed. Perhaps combination
of PPI and inhibitors of cyclooxygenase in chemopre-
vention of adenocarcinoma of the oesophagus may
provide a beneficial effect.
Numerous studies point to the protective effect of
NSAIDs – especially selective COX-2 inhibitors – in
the prevention of oesophageal and colorectal cancer
[14]. Studies on their application in chemoprevention
of gastrointestinal cancers were discontinued due to
important side-effects of rofecoxib discovered during
the study for colorectal cancer prevention (Adenoma-
tous Polyp PRevention On Vioxx – APPROVe). The risk
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of heart attack or stroke was doubled among
patients taking this medication [15]. Farrow demon-
strated significantly reduced risk of both adenocarci-
noma and squamous cell cancer of the oesophagus
in patients chronically using aspirin [28]. The multi-
centre programme ASPECT is currently focusing on
its effect on BE and cancer.
In patients undergoing argon plasma ablation,
effective eradication of metaplastic mucosa resulted
in marked reduction of COX-2 expression. Initially
overexpression of COX-2 was found in 21 patients
(70%) treated with the combination of APC and PPI
(group A) and 13 patients (65%) in whom APC abla-
tion was followed by the anti-reflux procedure 
(group B). After 12 months increased expression of
this enzyme was observed only in 6 patients of group A
and 3 of group B (Table III). The effect of ablative ther-
apy supplemented by administration of pantoprazole
or laparoscopic Nissen fundoplication was signifi-
cantly better compared to the control group with
respect to the level of expression of COX-2 (Table III).
Taking into consideration the documented role of
the cellular signalling pathway involving COX-2 in
carcinogenesis it might be concluded that argon plas-
ma ablation could be a superior method in preven-
tion of progression of Barrett’s metaplasia as com-
pared to anti-secretory treatment. The study failed to
demonstrate an advantage of laparoscopic Nissen
fundoplication over high doses of pantoprazole ther-
apy as a supplementary method after APC ablation.
Further studies are needed to fully document the val-
ue of COX-2 expression as a prognostic factor in the
development of more advanced forms of BE and ade-
nocarcinoma. It seems however that the level of
expression of COX-2 correlates well with the
histopathological findings in BE, particularly the level
of dysplasia. These conclusions are supported by the
documented relation of different types of metaplasia
with varying degrees of overexpression of COX-2.
Conclusions 
1. Overexpression of COX-2 can be documented in
most patients with BE, particularly those with asso-
ciated dysplasia. 
2. In most patients treatment results correlate with
the degree of overexpression of COX-2, which sug-
gests the value of this parameter as a possible bio-
marker of the development of oesophageal adeno-
carcinoma related Barrett’s metaplasia.
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